TIDMAREC

RNS Number : 0611A

Arecor Therapeutics PLC

18 January 2024

Arecor Therapeutics plc

("Arecor" or the "Group")

ARECOR GRANTED KEY EUROPEAN PATENT EXTENDING PROTECTION FOR INSULIN PRODUCTS, AT278 AND AT247

Cambridge, UK, 18 January 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, is pleased to announce that the European Patent Office has granted a patent ( EP3618840) protecting novel formulations of the Group's proprietary insulin products, AT278 and AT247. The European patent adds to a comprehensive global intellectual property (IP) portfolio protecting the Group's novel insulin products and follows additional patents of similar scope recently granted in Australia, India and Mexico.

Jan Jezek, Chief Scientific Officer at Arecor, commented : "We continue to build a strong intellectual property portfolio in key markets for our ultra-fast acting insulin products, AT278 and AT247, which provide the Group significant growth potential in a multi-billion dollar market driven by the need for tighter glucose control and the rise of innovative delivery devices and digital technologies. AT278, our 'disrupter insulin' with its high concentration and ultra-rapid profile has the potential to be the gold standard insulin for the growing population of people with high daily insulin needs and an essential component to enable patch pump miniaturisation and extended wear-time. Further data to support its profile are expected in H1 2024 from the Group's clinical trial in a type 2 diabetes population."

Arecor has built a comprehensive IP portfolio protecting the Group's Arestat(TM) technology platform and proprietary pipeline products. The portfolio, which comprises 36 patent families and >90 granted patents in Europe, the US and in other key territories, includes several patent families providing robust IP protection of the Group's proprietary insulin products until at least 2037.

-ENDS-

For more information, please contact:

 
 Arecor Therapeutics plc                    www.arecor.com 
 Dr Sarah Howell, Chief Executive Officer   Tel: +44 (0) 1223 426060 
                                             Email: info@arecor.com 
 
 Susan Lowther, Chief Financial Officer     Tel: +44 (0) 1223 426060 
                                             Email: info@arecor.com 
 
 Mo Noonan, Communications                  Tel: +44 (0) 7876 444977 
                                             Email: mo.noonan@arecor.com 
 
 Panmure Gordon (UK) Limited (NOMAD         Tel: +44 (0) 20 7886 2500 
  and Broker) 
  Freddy Crossley, Emma Earl (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking) 
 
 ICR Consilium 
 Chris Gardner, David Daley, Lindsey        Tel: +44 (0) 20 3709 5700 
  Neville                                    Email: arecor@consilium-comms.com

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat(TM) , we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat (TM) platform is supported by an extensive patent portfolio .

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCSFWFWWELSEFF

(END) Dow Jones Newswires

January 18, 2024 02:00 ET (07:00 GMT)

Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Arecor Therapeutics Charts.
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Arecor Therapeutics Charts.